Assessing biotech companies, focus of upcoming Lessons Learned
<p>On 5 July, investors and entrepreneurs will meet once again at the Barcelona Science Park</p>
What factors are involved in the assessment of a biotechnology company in the early stages? How can an entrepreneur negotiate a satisfactory assessment? Entrepreneurs and investors with experience in rounds of funding in the healthcare and life sciences sector will debate these topics and much more at the upcoming Lessons Learned session, entitled "Valoració de companyies. Més enllà dels números".
This is the third session of 2016 and will once again take place at the Barcelona Science Park, organized by Biocat and CataloniaBio. The event will feature Jordi Naval, general director of Fundació Bosch i Gimpera, as the moderator, as well as experts Carles Domènech, CEO of Ability Pharmaceuticals; Jordi Carrera, CEO of STAT-Diagnostica & Innovation; Daniel Oliver, director of Capital Cell; Alain Garcinuño, CFO of Anaconda BioMed; and Lluís Pareras, director of Healthequity.
The speakers will focus on the pre-money assessment of a biotech company in the early stages, as this has a direct impact on the dilution of the participation of entrepreneurs and the future return for investors. Moreover, the session will look at the consequences of an assessment that is too high or too low, which are often not taken into account.
The Lessons Learned program is a knowledge and networking forum geared towards professionals from companies in the life sciences arena. The aim is to share experiences and options in different strategic areas of knowledge and the skills needed to make biotechnology companies more competitive.
> Sign up
